Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma

Inclusion Criteria:

* CD138 or BCMA antigen positive multiple myeloma in patients with no available curative treatment options (such as autologous or allogeneic SCT).
* Relapsed and/or refractory multiple myeloma.
* Relapsed after prior autologous or allogenic SCT.
* Expected survival ≥ 3 months
* Creatinine \< 2.0 mg/dl
* Blood coagulation function: PT and APTT \< 2x normal
* Arterial blood oxygen saturation \> 92%
* Alanine Aminotransferase (ALT)/Aspartate Aminotransferase (AST) \< 3x normal
* Karnofsky scores ≥ 60 and ECOG score ≤ 2
* Adequate venous access for apheresis, and no other contraindications for leukapheresis
* Patients should not take system chemotherapy in one month and immunotherapy in three months prior to CART cells infusion.
* Voluntary informed consent is given

Exclusion Criteria:

* Pregnant or lactating women
* Uncontrolled active infection.
* Active hepatitis B or hepatitis C infection.
* Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
* Previously treatment with any gene therapy products
* Any uncontrolled active medical disorder that would preclude participation as outlined.
* HIV infection.
* History of myocardial infarction and severe arrhythmia in half a year
* Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).
* Patients with fever of unknown origin (T \> 38℃)